CEL-SCI reaches full enrollment in pivotal Phase 3 head and neck cancer study. No further patient enrollment is required in the pivotal Phase 3 head and neck cancer study by CEL-SCI Corporation for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). The accrual and treatment phases of the Phase 3 study are complete. All of the 928…